Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Published 2013 View Full Article

Authors

Keywords

Journal

CLINICAL CANCER RESEARCH

Volume 20, Issue 1, Pages 233-245

Publisher

American Association for Cancer Research (AACR)

Online

2013-10-29

DOI

10.1158/1078-0432.ccr-13-1777

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

CLINICAL CANCER RESEARCH

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Ask a Question. Answer a Question.